Mark Sheptoff Financial Planning LLC Purchases New Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Mark Sheptoff Financial Planning LLC acquired a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 588 shares of the company’s stock, valued at approximately $36,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 4,246,749 shares of the company’s stock worth $209,874,000 after acquiring an additional 62,164 shares during the period. Wellington Management Group LLP lifted its position in PROCEPT BioRobotics by 32.4% in the fourth quarter. Wellington Management Group LLP now owns 1,065,698 shares of the company’s stock valued at $44,663,000 after purchasing an additional 260,946 shares during the period. Bellevue Group AG boosted its holdings in PROCEPT BioRobotics by 0.5% in the 1st quarter. Bellevue Group AG now owns 890,114 shares of the company’s stock valued at $43,989,000 after purchasing an additional 4,768 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in PROCEPT BioRobotics by 8.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 627,822 shares of the company’s stock worth $31,027,000 after purchasing an additional 51,305 shares during the period. Finally, Point72 Europe London LLP increased its position in PROCEPT BioRobotics by 30.5% during the 4th quarter. Point72 Europe London LLP now owns 530,071 shares of the company’s stock worth $22,215,000 after purchasing an additional 123,800 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on PRCT shares. TD Cowen lifted their price target on PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a research note on Monday. Truist Financial boosted their target price on shares of PROCEPT BioRobotics from $74.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Bank of America increased their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Wells Fargo & Company boosted their price objective on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $78.17.

PROCEPT BioRobotics Trading Up 4.0 %

Shares of PRCT stock opened at $82.97 on Thursday. The stock has a market cap of $4.31 billion, a P/E ratio of -39.14 and a beta of 1.03. The company has a quick ratio of 6.49, a current ratio of 7.51 and a debt-to-equity ratio of 0.20. PROCEPT BioRobotics Co. has a fifty-two week low of $24.83 and a fifty-two week high of $85.81. The business has a fifty day simple moving average of $70.63 and a 200-day simple moving average of $62.14.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.02. PROCEPT BioRobotics had a negative net margin of 58.73% and a negative return on equity of 37.85%. The firm had revenue of $53.35 million during the quarter, compared to the consensus estimate of $50.10 million. During the same period last year, the firm posted ($0.56) EPS. The firm’s revenue for the quarter was up 61.2% on a year-over-year basis. On average, analysts forecast that PROCEPT BioRobotics Co. will post -1.88 earnings per share for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 44,867 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $80.11, for a total value of $3,594,295.37. Following the sale, the director now directly owns 197,453 shares of the company’s stock, valued at $15,817,959.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 44,867 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $80.11, for a total transaction of $3,594,295.37. Following the completion of the sale, the director now owns 197,453 shares of the company’s stock, valued at $15,817,959.83. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $82.51, for a total value of $2,062,750.00. Following the completion of the transaction, the chief financial officer now owns 96,096 shares in the company, valued at $7,928,880.96. The disclosure for this sale can be found here. Insiders have sold 154,892 shares of company stock worth $12,134,665 over the last quarter. 17.40% of the stock is currently owned by insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).